GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Genuine Parts Company (GPC) [hlAlert]

Rating:
Buy GPC
down 9.27 %

Genuine Parts Company (GPC) upgraded to Buy with price target $104 by Argus

Posted on: Thursday,  Jun 18, 2015  8:25 AM ET by Argus

Argus rated Buy Genuine Parts Company (NYSE: GPC) on 06/18/2015, when the stock price was $92.07. Since
then, Genuine Parts Company has lost 9.28% as of 01/14/2016's recent price of $83.53.
If you would have followed this Argus's recommendation on GPC, you would have lost 9.27% of your investment in 210 days.

Genuine Parts Company Biotech AG is a publicly traded biopharmaceutical company focused on discovering, developing and commercializing new anticancer drugs. GPC Biotech's lead product candidate satraplatin is an oral platinum-based compound that has shown highly statistically significant results for progression-free survival in a Phase three registrational trial as a second-line chemotherapy treatment in hormone-refractory prostate cancer. The U.S. FDA has granted fast track designation to satraplatin for this indication, and the rolling NDA submission process for this compound has been completed. Satraplatin was in-licensed from Spectrum Pharmaceuticals, Inc. GPC Biotech is also developing a monoclonal antibody with a novel mechanism-of-action against a variety of lymphoid tumors, currently in Phase 1 clinical development, and has ongoing drug development and discovery programs that leverage its expertise in kinase inhibitors.

Argus Research is an independent research firm, and our business is producing, distributing and marketing high-quality investment and economic research. Our recommendations - BUY, HOLD and SELL - reflect the judgment of an analyst about a company's prospects as an investment in terms of value, expected growth and risks. Argus Research does not bring companies public, advise companies on mergers and acquisitions, broker trades, make markets in stocks or manage money. Our independence allows us to make critical judgments about companies that we might not be so free to make were we competing for a firm's underwriting business. Because we're not a broker/dealer, we don't have "inventory" of a stock that we have to move with a tainted recommendation. We have developed a six-point system for analyzing the stocks in our Universe of Coverage. We believe that this system
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
6/18/2015 8:25 AM Buy
None
92.07 104.00
as of 8/27/2015
1 Week down  -2.50 %
1 Month down  -9.47 %
3 Months down  -9.27 %
1 YTD down  -9.27 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
2/28/2012 8:25 AM Hold
None
62.30
1/18/2011 4:25 PM Buy
None
50.89 60.00
1/28/2009 8:25 AM Buy
None
33.11 43.00

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy